NEW YORK (360Dx) – Many resource-limited regions suffer from high rates of hepatitis B virus infections, and chronic liver infection with HBV can lead to cirrhosis and liver cancer. Traditional HBV testing, requiring costly PCR-based assays and biopsies, is often too expensive for these regions, but new research suggests a potential $20 blood test could be used to determine if a person is a good candidate for antiviral treatment for the virus.